Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
T.GUD
Alternate Symbol(s):
KHTRF
Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select...
international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Jan 25, 2023 10:26am
RE:Eli Lilly drug was rejected
And regardless of any future success - not likely to make any impact on our sales. Just not competing in the expensive infusion space. IMO
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Jan 25, 2023 6:25am
RE:Eli Lilly drug was rejected
Real relevant to GUD...Ha..? Anything to coufuse and desperately losing fortune Aliasgold
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Jan 24, 2023 8:12pm
Eli Lilly drug was rejected
FDA Rejects Accelerated Approval for Lilly’s Alzheimer’s Drug Published on: January 23, 2023 Pharmaceutical Technology Editors &
...more
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Jan 24, 2023 5:21pm
RE:RE:RE:Endo watch ...
$5.11 today, soon and slowly breaching below $5 and than all hell will brake loose. One short seller senses that the propping buy back is over the party starts. I will be a buyer at $2
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Jan 24, 2023 5:16pm
RE:RE:Endo watch ...
No - sorry - I don't know. I'm not sure if those 15 drugs actually left Endo or if they were just moved to different portfolio or a combination of the two. I know "Plan B" was one
...more
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Jan 24, 2023 2:16pm
RE:RE:Endo watch ...
None, zero, nada
(6)
•••
curiousj
X
View Profile
View Bullboard History
Comment by
curiousj
on Jan 24, 2023 9:13am
RE:Endo watch ...
do you how much of that 15 drugs drop at Paladin was relicensed to Knight?
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Post by
Chianchin
on Jan 21, 2023 4:35pm
Explaining inflation in LATAM to Musgy/boy
GUD borrowed 32 million of a basket of LATAM Curencies. Lets use Argentina as an example where inflation is at Offically 100% but on the streets is double that more like 200%. VIs a Vi the US dollar
...more
(143)
•••
Eoj123
X
View Profile
View Bullboard History
Post by
Eoj123
on Jan 21, 2023 12:12pm
Low 5 dollars
Took a peak, still low 5 dollars. I'm shocked..... not really
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Jan 21, 2023 9:05am
RE:Endo watch ...
GUD and Endo can learn from eachothers how to keep losing more fortunes with old generics drugs. Much worst for GUD in burnig fires, inflation and leftist revolutions in latam
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Jan 21, 2023 8:56am
Endo watch ...
Endo is still a long way from solving its Opioid litigations - and - in selling off assets. By latest count, the Paladin asset base has dropped from 69 drugs (at peak) to 54 drugs (now) - about a 22%
...more
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Jan 20, 2023 7:32pm
RE:And Eli Lilly has work to do ...
For those who reads this forum, be Bug-sy mugsy refuses to say that GUD toke losse for the drug they purchased for 200 millions so he/she/it ignores the question
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Jan 20, 2023 7:13pm
And Eli Lilly has work to do ...
The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker
...more
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Jan 20, 2023 9:35am
RE:I will say this ...
How much profiits did GUD made?
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
One Property, One Focus on Advancing this Gold Project in Ontario